Samuel C. Blackman Sells 30,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total value of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. The trade was a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Day One Biopharmaceuticals Trading Down 0.5 %

DAWN stock opened at $12.75 on Friday. The firm has a 50-day moving average of $14.19 and a two-hundred day moving average of $14.04. The firm has a market capitalization of $1.29 billion, a PE ratio of -12.38 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a one year low of $11.94 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same period in the prior year, the business posted ($0.54) EPS. On average, equities research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DAWN. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $35.71.

Institutional Trading of Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC lifted its stake in Day One Biopharmaceuticals by 178.5% in the 3rd quarter. FMR LLC now owns 7,412,380 shares of the company’s stock worth $103,254,000 after acquiring an additional 4,750,936 shares in the last quarter. Braidwell LP increased its holdings in shares of Day One Biopharmaceuticals by 60.5% in the 3rd quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock valued at $67,893,000 after purchasing an additional 1,837,949 shares during the period. Vestal Point Capital LP lifted its position in shares of Day One Biopharmaceuticals by 100.0% in the third quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after purchasing an additional 1,250,000 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in shares of Day One Biopharmaceuticals by 65.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after purchasing an additional 1,157,825 shares during the period. Finally, First Turn Management LLC purchased a new position in Day One Biopharmaceuticals during the third quarter valued at approximately $13,204,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.